Stocktoria
NRX Pharmaceuticals, Inc. NRXP
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2017-11-20
NRX Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $0 | $0 | — | — | — | — | — | — | — |
| R&D expense | $3.8M | $6.2M | $13.4M | — | — | $17.0M | $20.3M | $10.6M | — | — |
| SG&A expense | $13.1M | $13.5M | — | — | — | — | — | — | — | — |
| Operating income | -$16.2M | -$18.5M | -$27.8M | — | — | -$44.3M | -$115.8M | -$51.4M | -$713,187 | -$1.0M |
| Interest expense | — | — | $120,000 | — | — | — | $18,000 | $56,000 | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — | — | $17,841 | $84,206 | $16,311 |
| Net income | -$28.6M | -$25.1M | -$30.1M | — | — | -$39.8M | -$93.1M | -$51.8M | $408,427 | $66,101 |
| EPS (diluted) | — | — | — | — | — | $-0.60 | $-1.98 | $-1.51 | — | — |
| Operating cash flow | -$14.1M | -$10.6M | -$21.7M | — | — | -$39.8M | -$37.7M | -$2.3M | -$792,731 | -$473,187 |
| Cash & equivalents | $7.8M | $1.4M | $4.6M | $8.9M | $15.0M | $20.1M | $27.6M | — | — | — |
| Total assets | $13.0M | $3.7M | $7.3M | $13.1M | $19.8M | $25.8M | $32.7M | $2.9M | $32.1M | $70.8M |
| Total liabilities | $28.9M | $26.9M | $19.0M | $19.3M | $22.6M | $18.4M | $11.9M | $46.7M | $2.6M | $1.3M |
| Shareholders' equity | -$15.9M | -$23.2M | -$11.7M | -$6.2M | -$2.8M | $7.4M | $20.8M | -$43.8M | -$4.8M | $5.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth | — | — | — | — | — | — | — | -12777.2% | +517.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.